BDX Quote, Financials, Valuation and Earnings

Baxter International, Inc. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of -34.8%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Baxter International, Inc.'s return on equity of -12.97%.

Becton, Dickinson & Co. has a consensus price target of $196.08, signalling upside risk potential of 26.91%. On the other hand Baxter International, Inc. has an analysts' consensus of $22.19 which suggests that it could grow by 33.05%. Given that Baxter International, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe Baxter International, Inc. is more attractive than Becton, Dickinson & Co..

Becton, Dickinson & Co. has a beta of 0.287, which suggesting that the stock is 71.313% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.622, suggesting its less volatile than the S&P 500 by 37.765%.

Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.3%. Baxter International, Inc. offers a yield of 2.17% to investors and pays a quarterly dividend of $0.01 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.

Becton, Dickinson & Co. quarterly revenues are $5.3B, which are larger than Baxter International, Inc. quarterly revenues of $3B. Becton, Dickinson & Co.'s net income of $382M is higher than Baxter International, Inc.'s net income of -$1B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 24.94x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.00x versus 0.76x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of 12.68%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Boston Scientific Corp.'s return on equity of 12.55%.

Becton, Dickinson & Co. has a consensus price target of $196.08, signalling upside risk potential of 26.91%. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.81 which suggests that it could grow by 60.48%. Given that Boston Scientific Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Boston Scientific Corp. is more attractive than Becton, Dickinson & Co..

Becton, Dickinson & Co. has a beta of 0.287, which suggesting that the stock is 71.313% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.

Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.3%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.3B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Becton, Dickinson & Co.'s net income of $382M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 24.94x while Boston Scientific Corp.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.00x versus 4.74x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of 27.89%. Becton, Dickinson & Co.'s return on equity of 6.94% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Becton, Dickinson & Co. has a consensus price target of $196.08, signalling upside risk potential of 26.91%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $605.08 which suggests that it could grow by 33.85%. Given that Intuitive Surgical, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe Intuitive Surgical, Inc. is more attractive than Becton, Dickinson & Co..

Becton, Dickinson & Co. has a beta of 0.287, which suggesting that the stock is 71.313% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.7%.

Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.3%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.3B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Becton, Dickinson & Co.'s net income of $382M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 24.94x while Intuitive Surgical, Inc.'s PE ratio is 55.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.00x versus 15.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 7.27% compared to Becton, Dickinson & Co.'s net margin of 16.39%. Becton, Dickinson & Co.'s return on equity of 6.94% beat West Pharmaceutical Services, Inc.'s return on equity of 17%.

Becton, Dickinson & Co. has a consensus price target of $196.08, signalling upside risk potential of 26.91%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $316.69 which suggests that it could grow by 24.29%. Given that Becton, Dickinson & Co. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Becton, Dickinson & Co. is more attractive than West Pharmaceutical Services, Inc..

Becton, Dickinson & Co. has a beta of 0.287, which suggesting that the stock is 71.313% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.152, suggesting its more volatile than the S&P 500 by 15.246%.

Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.3%. West Pharmaceutical Services, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.22 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.66% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.3B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $806M. Becton, Dickinson & Co.'s net income of $382M is higher than West Pharmaceutical Services, Inc.'s net income of $132.1M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 24.94x while West Pharmaceutical Services, Inc.'s PE ratio is 37.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.00x versus 6.02x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.